LTEP-a2人肺腺癌細(xì)胞、L
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/4/24 14:35:23
- 訪問(wèn)次數(shù) 89
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
LTEP-a2 人肺腺癌細(xì)胞
Catalogue No.: C1316
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%1640+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.
Components
| Item | Specifications |
| a T25 flask | 2X106 |
| Manual | 1 copy |
both patients with advanced pklanoma and those with advanced NSCLC. In patients with advanced pklanoma, both PD-1 inhibitors (nivolumab and pembrolizumab) have shown improved survival versus ipilimumab. PD-1 inhibitors are associated with adverse events that have immune
采購(gòu)中心
化工儀器網(wǎng)